Skip to content
OpenCapital
Get started

West Pharmaceutical Services WST Proprietary Products — CapEx

Other segment segments

West Vantage
$5.6M—

Similar metrics at other companies

Balchem logo
BCPCSpecialty Products — CapEx
$597K-17.3%
Arcosa logo
ACAConstruction Products — CapEx
$31.9M+30.7%
Park-Ohio Holdings logo
PKOHEngineered Products — CapEx
$4.7M+51.6%
Motorola Solutions, Inc. logo
MSIProducts and Systems Integration — CapEx
$25M+66.7%
XER
XERSCapEx
-$325K-2,400%
DocGo logo
DCGOCorporate — CapEx
$635.27K-81.3%

Other financials

Income statement

See full
Revenue$844.9M+21.0%
Gross profit$296.4M+27.8%
Operating income$177.1M+65.5%
Net income$138.8M+54.6%
EPS (diluted)$1.92+56.1%

Balance sheet

See full
Cash & equivalents$521.4M+29.0%
Total debt$321.0M+4.4%
Total equity$3.0B+11.5%
Total assets$4.1B+13.6%

Cash flow

See full
Operating cash flow$89.9M-30.5%
CapEx$42.7M-40.1%
Free cash flow$47.2M-18.8%

Valuation

See full
Market cap$25.36B+64.2%
Enterprise value$25.16B+65.1%
P/E46.7×+15.1×
P/S7.9×+2.7×

Profitability

See full
Gross margin36.3%+1.7pp
Operating margin20.3%+1.2pp
Net margin16.8%+0.7pp
FCF margin14.2%+3.6pp

Returns & leverage

See full
Return on equity19.1%+1.7pp
Debt / equity0.1×0.0×
Current ratio2.7×-0.1×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:SegmentExpenditureAdditionToLongLivedAssets.

The official record: West Pharmaceutical Services’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about West Pharmaceutical Services's proprietary products — capex.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is West Pharmaceutical Services's proprietary products — capex?
West Pharmaceutical Services (WST) reported proprietary products — capex of $36.5M in Q1 2026.
How has West Pharmaceutical Services's proprietary products — capex changed year-over-year?
West Pharmaceutical Services's proprietary products — capex decreased by 29.7% year-over-year, from $51.9M to $36.5M.
What is the long-term trend for West Pharmaceutical Services's proprietary products — capex?
Over 4 years (2021 to 2025), West Pharmaceutical Services's proprietary products — capex has grown at a -1.6% compound annual growth rate (CAGR), from $218M to $204.3M.
What does proprietary products — capex mean?
This represents the cash outflows used to acquire, upgrade, or maintain physical assets such as property, plants, and equipment within the proprietary products segment. It is a primary measure of the company's commitment to long-term growth and capacity expansion.